Ionis Pharmaceuticals, Inc.
Compositions and methods for modulating Ataxin 3 expression

Last updated:

Abstract:

Disclosed are methods for modulating splicing of Ataxin 3 mRNA in an animal with modified oligonucleotides. Such compounds and methods are useful to treat, prevent, or ameliorate spinocerebellar ataxia type 3 (SCA3) in an individual in need thereof.

Status:
Grant
Type:

Utility

Filling date:

26 Nov 2019

Issue date:

5 Apr 2022